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The expression of the DBP (vitamin D binding protein) gene was investigated in monocytes and in peripheral blood lymphocytes. DBP message 
was amplified through 35 cycles of PCR amplification using specific oligonucleotide primers. PCR products of the expected size were further 
identified by Southern blotting using a specific DBP probe. No expression of the DBP gene could be detected in peripheral blood lymphocytes, 
nor in the monocyte-derived U 937 cell line. In contrast. message for DBP was identified in monocytes activated with lipopolysaccharide when 
analyzed between 6 and 10 h following stimulation. These results suggest that the temporal expression of the DBP gene could play a major role 
in the activation of monocytes by 1-25tOH)zD,. 
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1. INTRODUCTION 
Vitamin D binding protein (DBP), a 56,000 m.wt. 
a2-globulin, represents the major serum carrier for vita- 
min D metabolites [1,2]. In addition, it binds actin [3,4] 
and facilitates depolymerization of filamentous F actin 
to the globular (G) form [5]. DBP also binds unsatu- 
rated fatty acids [6] and, at the cellular level, it has been 
shown to enhance neutrophil chemotactic activity of 
C5a and C5a des Arg [7,8]. Preincubation of DBP with 
1,25(OH),D, completely abolishes its cochemotactic ac- 
tivity [9]. suggesting that binding of vitamin D may 
modify different functions of DBP. 
In the early eighties it was shown, by indirect im- 
munofluorescence, that DBP is present on intact lym- 
phocytes [lo]. The protein is expressed on B lymphocyte 
membranes and closely associated with surface immu- 
noglobulins [ll]. DBP is also expressed on monocytes 
[12]. Further studies suggested that DBP is selectively 
related, on B lymphocyte membranes, to surface IgM, 
although it was not found on lymphocyte from B 
chronic lymphocytic leukemia carrying different sub- 
classes of immunoglobulins [ 131. Resting T lymphocytes 
are mostly negative for surface DBP but the protein is 
expected to be present on activated T lymphocytes 
where it has been demonstrated to be related to the Fc 
y receptor [14,15]. It has been demonstrated that the 
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protein is hidden in part in the membrane of circulating 
monocytes [16]. This suggests that DBP could play sev- 
eral roles at the cell membrane level in addition to mod- 
ulate the effects of vitamin D on lymphocytes [17]. This 
is confirmed by the finding that an antiserum against 
DBP inhibits human natural killer activity [18]. Thus 
DBP seems to be possessing a major potential role in the 
immune function. In this view. it will be quite surprising 
that any immunocompetent cell is not involved in DBP 
synthesis. It has been generally accepted that DBP is 
synthesized by liver [2]. In all rat tissues examined low 
levels of DBP RNA transcripts could be detected 
by polymerase chain reaction [19]. In humans extra- 
liver synthesis of DBP has not been demonstrated. By 
Northern blot analysis, DBP gene expression was not 
detected in several cells, including B lymphocytes, rest- 
ing and stimulated T lymphocytes, the B lymphoblas- 
toid cell line GM 1500, the T-cell lymphoma Sup Tl cell 
line and placental cytotrophoblast cells [20]. The mono- 
blastic human cell line U 937 was also checked for DBP 
expression both by Northern blot and by PCR but no 
specific signal was found [20]. As monocytes are in- 
volved in synthesis of 1,25(OH),D, [21] and show major 
reactivity to anti DBP antibodies [12] we decided to 
reevaluate the expression of DBP in resting and LPS 
activated human normal monocytes. Monocyte de- 
pleted human peripheral blood lymphocytes and U 937 
cells were also examined. 
2. MATERIALS AND METHODS 
2.1 Cells 
Hep 3B cells (human hepatoma cell line) were routinely cultured in 
Eagle’s minimal essential medium, supplemented with L-glutamine (2 
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mM). penicillin (100.000 U/l). streptomycm (100 mg/l), fungtzone (250 
mg/l) and 10% fetal calf serum (FCS), and Incubated at 37°C m a 
humtdtfied atmosphere of 5% CO, in air. 
U 937 cells were continuously cultured at 37°C. 5% CO, in RPM1 
1640 supplemented with 10% FCS, 1% glutamine 200 mM and gen- 
tamycin 100 mg/ml. Cells were sub-cultured twice a week and resus- 
pended at a concentration of 5 x 105/ml. Cells were examined m the 
log growth phase 
Human lymphocytes were recovered from peripheral blood ob- 
tained from healthy donors after Lymphoprep purtficatton. Mononu- 
clear cells were recovered and allowed to adhere to plastic dishes at 
the concentration of lO’/dish m PBS with Ca’+ and Mg’+ plus 20% 
FSC at 37°C (5% CO,) for 1 h. The supernatant was recovered and 
cells resuspended in fresh PBS supplemented with 20% FCS and al- 
lowed to adhere for an additional 60 min Monocytes m the recovered 
cell populations were <I% as resulted by cytofluortmetrtc analysis 
using CD 14 monoclonal antibody. Lymphocytes were then pulsed 
with LPS 10 ,ug/ml. 
Monocytes were recovered from healthy donors from mononuclear 
cells partially purified by differential centrifugation with an apparatus 
for cyto-apheresis. Cells representing ~90% mononuclear were stored 
m liquid nitrogen m 10% DMSO. The experiments were conducted 
with cells washed m PBS with Ca” and Mg’+ supplemented wtth 20% 
FCS and allowed to adhere in plastic dishes at a concentration of 
15 x 106/ml. After 1 h at 37°C the supernatant was discarded and the 
dishes were washed three times with 37°C PBS. Adherent cells were 
>80% monocytes as shown by cytofluorimetrtc analysis with CD14 
monoclonal antibody and cytochemtcal reaction for alpha naphthyl 
butyrate esterase. 10 ml of PBS supplemented with 20% FCS were then 
added to the dashes together with LPS at a final concentration of 10 
pg/ml. Both lymphocyte and monocyte enrtched populattons were 
tested for specific mRNA after 0, 3, 6, 10. 24. 30 h followmg the LPS 
stimulation. 
2.2. RNA isolutron and reverse transcript~ot~ (RT) 
Total RNA from human monocytes, lymphocytes, Hep 3B and U 
937 cell lines was isolated following the acid guanidinmm thtocyanatee 
phenol/chloroform method [22] 
Total RNA was then reverse-transcribed mto cDNA as follows: 2 
~1 of each sample (200 ng) were mixed with a solution containing 5 
mM MgC&, 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1 mM each dNTP 
(Perkm-Elmer), 2.5 mM random hexamers (Perkin-Elmer-Cetus), 1 
U/p1 RNase inhibitor (Perkin-Elmer-Cetus). 2.5 U/p1 reverse tran- 
scriptase (Perkin-Elmer-Cetus) in a final volume of 20 ~1. 
2.3. Ohgonucleotide synthesis 
The downstream (5’-GTGCACACAAAAACGTCC-3’) and up- 
stream (5’-GTCCTGCTGTACCTCTGC-3’) primers for human DBP 
were designed to amphfy a 375 bp fragment and span exon-intron 
boundaries in order to prevent contamination of the amplification 
product of mRNA by amplified genomic DNA. 
Ohgonucleotides were synthesized on an automated obgonucleottde 
synthesizer (Applied Biosystems, Model #380B. Foster City. CA) and 
desalted through a Sephadex G-25 column. Purity was assessed by 
electrophoresis on a 15% polyacrylamide gel containing 7 M urea 
2.4. PCR 
The PCR reaction was carried out m a final concentratton of 2 mM 
MgCIZ, 50 mM KCl. 10 mM Tris-HCl, pH 8.3, 0.2 mM dNTP. 2.5 
U/l00 ml AmphTaq DNA polymerase (Perkm-Elmer Cetus). and 0. I5 
mM of each primer. The mixture was overlayed vvtth mmeral oil and 
amplified using a DNA thermal cycler (Perkm-Elmer Cetus). The 
amplification program was set to denature at 95°C for 1 mm. anneal 
at 55°C for 1 mm and extend at 70°C for I min for a total of 35 cycles. 
The absence of contaminants was routinely checked by running 
control samples that contained no RNA. no reverse transcriptase or 
only the PCR reaction buffer. 
2.5. DBP probe 
A clone was isolated from a human liver cDNA expression library 
made m hgtl 1 (a gift from Frank Gonzales, Laboratory of Molecular 
Carcinogenesis. National Cancer Institute) using specific anttDBP 
antibodies. The insert was excised from the purified phage using 
EcoRI digestion, and the four fragments obtained (140, 310, 505, 776 
bp, respectively) were subcloned mdividually in the phagemid 
p-Bluescrtpt SKII (Stratagene) and sequenced using the dtdeoxy 
method of Sanger. Their sequence shohed to be identical to that 
published m the literature [23.24]. 
The 505 bp fragment uas used as a probe for the hybrtdization 
procedure. The H-DBP probe was biotmylated by nick translatton and 
the reactton was performed according to the ‘non-tsotoptc system for 
DNA probe labeling’ (Oncor, Gaithersburg, MD). 
2.6 Southern blot (I~(I/~~JIS 
8 ~1 of each PCR product were electrophoresed m a 5% acrylamide 
gel (75 volts for 90 mm), stained with ethidmm bromide and photo- 
graphed. After an mcubatton in a 0.25 N final concentration of sodium 
hydroxide (10 min at room temperature). samples were blotted onto 
a nylon membrane (Oncor, Gatthersburg. MD) which was baked for 
1 h at 80°C. Hybridization was performed overnight at 42°C using 25 
ng/ml final concentration of btotmylated HDBP probe. The filter was 
then washed twice m 0. I6 x SSC and 0.1% SDS at room temperature 
for 5 min, once at 50°C for 30 min m 0 16 x SSC. 0 1% SDS and wash 
Enhancer (80 ,&lOO ml) (Oncor. Gatthersburg. MD) and two more 
times in 1 x SSC at room temperature for 5 mm. The iilter v+as then 
developed with the ‘Oncor non-tsotoptc system for detection’ based on 
the biotin/streptavtdin/alkahne-phosphataae mteractton. 
The presence of DBP on the membrane surface of cells was exam- 
ined by immunofluorescence. Briefly, cells were washed m cold PBS 
containing 0.1% sodium aztde and then incubated for 30 mm at 4°C 
with 10% of rabbit IgG to human DBP (Dako) After appropriate 
washing. cells were Incubated wtth a fluoresceinated s&ine anti rabbit 
Ig antiserum. After appropriate washes cells were exammed under a 
fluorescence microscope and a cytofluortmetric apparatus. Approprt- 
ate negative controls were performed. Spectficny of the rabbit anti 
human DBP antibody has been previously reported [l 11. In particular. 
no cross reactivity between anti human DBP Ig and FCS was detected 
by Outcherlony double diffusion method. Results were expressed as 
percentage of positive cells. 
Oligonucleotides 
Table I 
Sequence of the ohgonucleotides used as primers for PCR amplification 
Nucleotide position Polarity Sequences (5’ --f 3’) Ref. 
1 H-DBP primer I 
2 H-DBP primer II 
589-606 (+) GTCCTGCTGTACCTCTGC 1251 
963-946 (-) GTGCACACAAAAACGTCC [251 
90 
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3. RESULTS 
DBP was detected by immunofluorescence on >80% 
of monocyte enriched human peripheral blood cells and 
in 20% monocyte depleted cells. DBP positivity ap- 
peared as minute bright granules on cell membranes. U 
937 cells were negative for DBP. 
Total RNA obtained from Hep 3B and U 937 cell 
lines and from human lymphocytes and monocytes (be- 
fore and after LPS stimulation) was subjected to RT/ 
PCR analysis to study the human DBP gene expression. 
Hep 3B cell line was selected as a positive control since 
it has been shown to express the DBP gene [24] and 
secrete the DBP protein [25]. 
As described in section 2, the oligonucleotides were 
designed so that the mRNA amplification product (375 
bp) would not be confused with any genomic DNA 
contamination. 
The PCR products were first analyzed by gel electro- 
phoresis and ethidium bromide staining. At this stage 
monocytes after 6 and 10 h from LPS stimulation and 
Hep 3B were positive for the 375 bp fragment when all 
the other samples showed a number of faint, non spe- 
cific bands but not that of the expected size (Fig. 1). 
Samples were then blotted onto a nylon membrane and 
hybridized with the biotinylated human DBP probe to 
determine the presence of a specific amplification prod- 
uct. This procedure demonstrated that the band found 
in monocytes after a 6 and 10 h stimulation was specific 
for DBP (Fig. 2). Resting and monocytes stimulated for 
3, 24, 30 h, resting and stimulated lymphocytes and U 
937 cells were completely negative. 
1 2-3 
Fig. 1. Ethidium bromide-stained 5% acrylamide gel for DBP PCR 
products (expected size 375 bp). Lanes l-5, LPS activated monocytes 
after. respectivrly, 0. 3. 6. 10, 24 h of incubatton. Lane 6, Hep 3B cell 
line. Lane 7, molecular weight marker (EcoRI digested p-Bluescript 
SK II (2,961 bp)) containing the four subcloned fragments of human 
DBP cDNA (140. 310. 505, 776, respectively). Lane 8. U 937 cell line. 
4. DISCUSSION 
DBP is present on the surface of several human cells 
including native B lymphocytes and monocytes. At the 
present time, no definitive data showing the origin of 
Fig. 2. Southern blot of PCR products for DBP. Products of PCR were run in a 5% acrylamide gel, electrophoretically transferred on a nylon 
membrane and hybrtdized with a btotinylated EcoRI fragment (505 bp) of DBP cDNA. Lane I. empty. Lanes 2-7, monocytes acttvated with LPS 
for 0, 3. 6, 10, 24, 30 h, respectively. Lane 8. the four fragments obtained after EcoRI digestion of human DBP (140, 310, 505, 776) were run in 
this lane. AS expected only the 505 bp fragment hybridized with the biotinylated specific probe. Lanes 9-10. empty. 
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membrane DBP have been reported. In a previous work 
we were not able to show any specific binding of DBP 
on native peripheral blood cells [ll]. Since then, albu- 
min, which is structurally and evolutionarily related to 
DBP, has been shown to bind with specificity, saturabil- 
ity and reversibility to a number of cells [26,27]. The 
origin of DBP bound on human peripheral cells is un- 
known. By contrast, it has been clearly demonstrated 
that blood peripheral cells as well as several cell lines 
including U 937 do not express any message for this 
protein [20]. Although the positivity of U 937 by im- 
munofluorescence had been related to a cross reactivity 
of the anti human DBP with DBP present in fetal calf 
serum [20], in our experiments U 937 was completely 
negative suggesting that this cross reactivity was not 
present in our antiserum. In agreement with a previous 
report [20] we could not detect any message following 
PCR amplification in U 937 cells nor in monocyte de- 
pleted human peripheral blood lymphocytes or resting 
monocyte enriched cells. 
In contrast, a clear specific message was found in 
human monocytes (but not in lymphocytes) after LPS 
stimulation. This positivity was present only at 6 and 10 
h after LPS stimulation. Thus a possible synthesis of 
DBP may have happened during a very restricted period 
of time following monocyte activation. It is logical to 
postulate that DBP present on monocytes derives at 
least partially from this synthesis. DBP has been postu- 
lated to prevent several activities of vitamin D,, and, in 
this respect. 1,25(OH),D, is known to play a major role 
on monocyte/macrophage activities and especially dur- 
ing the process of differentiation [28]. It is therefore 
possible that synthesis of DBP during the early phase 
of monocyte activation could protect cells from vitamin 
D, activity. In this respect, y interferon-induced pro- 
duction of 1,25(OH)?D, is detectable after 24 h of cul- 
ture. Thus these phenomena appear temporally sepa- 
rated during cell activation. At the beginning of the 
activation production of DBP for a short period of time 
could prevent the vitamin D, effect resulting in mono- 
cyte differentiation; later, a suppression of DBP syn- 
thesis together with the synthesis of 1,25(OH),D, in 
monocytes induced by y interferon could contribute to 
control both monocyte and lymphocyte functions. The 
fact that DBP is synthesized by monocytes does not 
mean that the bound protein does not originate from 
plasma. although the deep location of DBP in the mono- 
cyte membranes [I 61 is not in favor of the latter. In 
contrast, this could be the case for lymphocytes where 
specific mRNA is not present even following PCR am- 
plification. However, our results do not rule out the 
possibility that DBP synthesis could occur in lympho- 
cytes activated by different mechanisms. 
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